NASDAQ:INDP - US45339J1051 - Common Stock
The current stock price of INDP is 3.303 USD. In the past month the price decreased by -50.99%. In the past year, price decreased by -91.75%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.07 | 375.50B | ||
AMGN | AMGEN INC | 13.01 | 152.70B | ||
GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.89 | 40.63B | ||
INSM | INSMED INC | N/A | 30.67B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
NTRA | NATERA INC | N/A | 23.06B | ||
BIIB | BIOGEN INC | 8.79 | 20.62B |
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
INDAPTUS THERAPEUTICS INC
3 Columbus Circle, 15th Floor
New York City NEW YORK US
CEO: Jeffrey A. Meckler
Employees: 7
Phone: 16464272727
The current stock price of INDP is 3.303 USD. The price decreased by -28.35% in the last trading session.
The exchange symbol of INDAPTUS THERAPEUTICS INC is INDP and it is listed on the Nasdaq exchange.
INDP stock is listed on the Nasdaq exchange.
7 analysts have analysed INDP and the average price target is 184.11 USD. This implies a price increase of 5474.02% is expected in the next year compared to the current price of 3.303. Check the INDAPTUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INDAPTUS THERAPEUTICS INC (INDP) has a market capitalization of 3.67M USD. This makes INDP a Nano Cap stock.
INDAPTUS THERAPEUTICS INC (INDP) currently has 7 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INDP does not pay a dividend.
INDAPTUS THERAPEUTICS INC (INDP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-29.01).
The outstanding short interest for INDAPTUS THERAPEUTICS INC (INDP) is 2.1% of its float. Check the ownership tab for more information on the INDP short interest.
ChartMill assigns a fundamental rating of 2 / 10 to INDP. The financial health of INDP is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months INDP reported a non-GAAP Earnings per Share(EPS) of -29.01. The EPS decreased by -1451.34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -291% | ||
ROE | -562.48% | ||
Debt/Equity | 0 |
7 analysts have analysed INDP and the average price target is 184.11 USD. This implies a price increase of 5474.02% is expected in the next year compared to the current price of 3.303.